75%Confidence
0Views
FDASource
2026-04-08Date
Summary
Annora Pharma's Class III recall for cross-contamination of Pitavastatin tablets represents a medication mix-up that could confuse patients but poses lower health risks. This suggests quality control failures in packaging operations that need addressing to prevent more serious errors.
Actionable: Review Annora Pharma's quality systems and consider the potential for more stringent FDA oversight of their manufacturing processes.
AI Confidence: 75%
Data Points
firmAnnora Pharma Private Limited
classificationClass III
statusOngoing
distributionTN
productPitavastatin Tablets, 2 mg, packaged in 90-count bottles, Rx only, Manufactured for: Northstar Rx LLC, Memphis, TN 38141, Manufactured by: Annora Phar
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now